Retatrutide (also known as LY3437943) is a novel triple agonist peptide that simultaneously targets three key metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This tripartite mechanism distinguishes retatrutide from dual agonists such as tirzepatide, potentially offering enhanced efficacy in metabolic research models.
In preclinical and early-phase research, retatrutide has demonstrated significant interest in the areas of energy expenditure regulation, adipose tissue reduction, and glycaemic control. The glucagon receptor component is believed to contribute to increased hepatic glucose output suppression and thermogenesis, whilst GLP-1 and GIP activity supports insulin secretion modulation and appetite signalling pathways.
This 30mg vial is supplied as a lyophilised powder with a purity of >98% as verified by HPLC analysis. Molecular formula: C₂₂₄H₃₅₀N₅₈O₆₈S. Molecular weight: approximately 4963.5 g/mol. CAS number: 2381272-77-9.
Storage: Lyophilised peptide should be stored at -20°C and kept away from direct light and moisture. Once reconstituted, store at 4°C and use within an appropriate research timeframe.
Molecular Formula
C₂₂₄H₃₅₀N₅₈O₆₈S
Molecular Weight
4963.5 g/mol
Purity
>98%
CAS Number
2381272-77-9
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Obesity and adiposity models, Glycaemic regulation studies, Energy expenditure and thermogenesis, Hepatic glucose metabolism, Appetite and satiety signalling
For research purposes only. Not for human use.
Reviews
There are no reviews yet.